Zynerba Scraps Development of THC Prodrug ZYN001 after Failed Trial

Cannabinoid-based drug developer Zynerba Pharmaceuticals said today it will halt development of its D-glyceric acid ester-delta-9-tetrahydrocannabinol (THC) prodrug candidate ZYN001 following its failure in a clinical trial, and instead refocus its development effort and investment on its cannabidiol (CBD) permeation-enhanced gel ZYN002.ZYN001 had been in clinical development for Tourette syndrome and preclinical development for additional undisclosed indications. Zynerba said ZYN001 missed its